BioVectis

BioVectis designs, manufactures and commercializes precision Life‑Science R&D tools and advances complementary therapeutics and diagnostics, leveraging 20+ years of academic collaborations.

Select portfolio

·         Scutum_IO — neoepitope discovery pipeline to accelerate personalized cancer vaccines.

·         Appus — natural‑origin preclinical candidate for autoimmune/inflammatory disease with robust safety and efficacy signals (CIA model).

·         DNAPointer® System — flagship native slab‑gel platform with ±0.1 °C control for protein complexes (-protein, -membrane, -nucleic acids) native high‑resolution separation and preparative recovery; workflows for MS/NGS and cryo‑EM/NMR.

·         AgePlex™ Kit — five‑CpG epigenetic human biological age assay (~3.4 years MAE) for forensics, wellness and research.

·         Scutum_ND — rHVT recombinant vaccine (NDV + Marek’s) with pilot field efficacy >98% and DIVA diagnostics; compatible with in‑ovo automation.

·         VelaMed — point‑of‑care VOC diagnostic (DMS + ML) with AUC >0.98 for IBD detection; applications in human diagnostics and livestock/food QC.

We seek

·         R&D partners, seed investors, distributors and grant collaborators.